• 1
    Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996; 11: 12771285.
  • 2
    Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 200112: 27682774.
  • 3
    Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol. 2001; 12: 10791084.
  • 4
    Zoccali C, Mallamaci F, Tripepi G, et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40: 4146.
  • 5
    Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002; 62: 339345.
  • 6
    Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007; 72: 10041013.
  • 7
    Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005; 288: E125E132.
  • 8
    Nibbelink KA, Tishkoff DX, Hershey SD, Rahman A, Simpson RU. 1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. J Steroid Biochem Mol Biol. 2007; 103: 533537.
  • 9
    Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 Vitamin D3 and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97: 15771588.
  • 10
    Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA. 2007; 104: 1681016815.
  • 11
    McGonigle RJ, Fowler MB, Timmis AB, Weston MJ, Parsons V. Uremic cardiomyopathy: potential role of vitamin D and parathyroid hormone. Nephron. 1984; 36: 94100.
  • 12
    Park CW, Oh YS, Shin YS, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis, 1999; 33: 7381.
  • 13
    Kim HW, Park CW, Shin YS, et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract. 2006; 102: c21c29.
  • 14
    Davey SG, Ebrahim S. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003; 32: 122.
  • 15
    Marco MP, Craver L, Betriu A, Fibla J, Fernandez E. Influence of vitamin D receptor gene polymorphisms on mortality risk in hemodialysis patients. Am J Kidney Dis. 2001; 38: 965974.
  • 16
    Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16: 1215.
  • 17
    Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 21132117.
  • 18
    De Simone G, Daniels SR, Devereux RB, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992; 20: 12511260.
  • 19
    Zoccali C, Mallamaci F, Tripepi G, et al. Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients: CREED investigators. J Hypertens 1999; 17: 17511758.
  • 20
    Lunetta KL. Genetic association studies. Circulation 2008; 118: 96101.
  • 21
    Verdecchia P, Angeli F, Pittavini L, Gattobigio R, Benemio G, Porcellati C. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients. Ital Heart J. 2004; 5: 505510.
  • 22
    Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 2004; 65: 14921498.
  • 23
    London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001; 12: 27592767.
  • 24
    Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007; 298: 12911299.
  • 25
    Thakkinstian A, D'Este C, Eisman J, Nguyen T, Attia J. Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. J Bone Miner Res. 2004; 19: 419428.
  • 26
    Valdivielso JM, Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta. 2006; 371: 112.
  • 27
    Erturk S, Kutlay S, Karabulut HG, et al. The impact of vitamin D receptor genotype on the management of anemia in hemodialysis patients. Am J Kidney Dis. 2002; 40: 816823.
  • 28
    Krause R, Roth HJ, Edenharter G, et al. Vitamin D deficiency and cardiac mortality in patients on renal replacement therapy (RRT). American Society of Nephrology Congress, 2008, abstract F-FC322 JASN 19, abstract issue 73A.
  • 29
    London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007; 18: 613620.